Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis

International Journal of Cardiology

Volumn 259, Issue , 2018, Pages 198-204

  Simon, Tracey G ^a   Trejo, Maria Esther Perez ^b   McClelland, Robyn ^b   Bradley, Ryan ^c   Blaha, Michael J ^d   Zeb, Irfan ^e   Corey, Kathleen E ^a   Budoff, Matthew J ^f   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e BRONX LEBANON HOSPITAL CENTER   (United States)

^f HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Biomarker; Cardiovascular disease; Fatty liver; Inflammation; Nonalcoholic fatty liver disease

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA GLUTAMYLTRANSFERASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN;

ADULT; ALCOHOL CONSUMPTION; ANALYTICAL PARAMETERS; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; DISEASE SEVERITY; ELECTRON BEAM TOMOGRAPHY; FEMALE; HUMAN; LIVER SPLEEN RATIO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; X-RAY COMPUTED TOMOGRAPHY; AGED; BLOOD; CORONARY ARTERY DISEASE; ETHNIC GROUP; ETHNOLOGY; MIDDLE AGED; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; COHORT STUDIES; CORONARY ARTERY DISEASE; ETHNIC GROUPS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 85044109366     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2018.01.046     Document Type: Article

References (44)

1. Lazo, M., Hernaez, R., Eberhardt, M.S., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am. J. Epidemiol. 178 (2013), 38–45.
2. Kim, D., Kim, W.R., Kim, H.J., et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57 (2013), 1357–1365.
3. Bonci, E., Chiesa, C., Versacci, P., et al. Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: a systematic review and meta-analysis. Biomed. Res. Int., 2015, 2015, 213737.
4. Coulon, S., Francque, S., Colle, I., et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 59 (2012), 442–449.
5. Jones, S.A., Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol. 175 (2005), 3463–3468.
6. Esteve, E., Castro, A., Lopez-Bermejo, A., et al. Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care 30 (2007), 939–945.
7. Lee, W.Y., Allison, M.A., Kim, D.J., et al. Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am. J. Cardiol. 99 (2007), 99–102.
8. Interleukin-6 Receptor Mendelian Randomisation Analysis C, Swerdlow, D.I., Holmes, M.V., et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379 (2012), 1214–1224.
9. Collaboration IRGCERF, Sarwar, N., Butterworth, A.S., et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379 (2012), 1205–1213.
10. Kaptoge, S., Seshasai, S.R., Gao, P., et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur. Heart J. 35 (2014), 578–589.
11. Ajmera, V., Perito, E.R., Bass, N.M., et al. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology 65 (2017), 65–77.
12. Bild, D.E., Bluemke, D.A., Burke, G.L., et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am. J. Epidemiol. 156 (2002), 871–881.
13. Al Rifai, M., Silverman, M.G., Nasir, K., et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 239 (2015), 629–633.
14. Jenny, N.S., Olson, N.C., Allison, M.A., et al. Biomarkers of key biological pathways in CVD. Glob. Heart 11 (2016), 327–336 (e3).
15. Bradley, R., Fitzpatrick, A.L., Jenny, N.S., et al. Associations between total serum GGT activity and metabolic risk: MESA. Biomark. Med 7 (2013), 709–721.
16. EM, DeGoma, French, B., Dunbar, R.L., et al. Intraindividual variability of C-reactive protein: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 224 (2012), 274–279.
17. Zheng, D., Zeng, F., Cai, A., et al. Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. Lipids Health Dis., 13, 2014, 41.
18. Arnett, D.K., RL, McClelland, Bank A, et al. Biomarkers of inflammation and hemostasis associated with left ventricular mass: the Multiethnic Study of Atherosclerosis (MESA). Int J Mol Epidemiol Genet 2 (2011), 391–400.
19. Carr, J.J., Nelson, J.C., Wong, N.D., et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology 234 (2005), 35–43.
20. Agatston, A.S., Janowitz, W.R., Hildner, F.J., et al. Quantification of coronary artery calcium using ultrafast computed tomography. J. Am. Coll. Cardiol. 15 (1990), 827–832.
21. Tota-Maharaj, R., Blaha, M.J., Zeb, I., et al. Ethnic and sex differences in fatty liver on cardiac computed tomography: the multi-ethnic study of atherosclerosis. Mayo Clin. Proc. 89 (2014), 493–503.
22. American Heart A, National Heart L, Blood I, et al. Diagnosis and management of the metabolic syndrome. an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Executive summary. Cardiol. Rev. 13 (2005), 322–327.
23. Schmidt-Arras, D., Rose-John, S., IL-6 pathway in the liver: from physiopathology to therapy. J. Hepatol. 64 (2016), 1403–1415.
24. Bastard, J.P., Jardel, C., Bruckert, E., et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. 85 (2000), 3338–3342.
25. Schieffer, B., Selle, T., Hilfiker, A., et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 110 (2004), 3493–3500.
26. Guo, F., Dong, M., Ren, F., et al. Association between local interleukin-6 levels and slow flow/microvascular dysfunction. J. Thromb. Thrombolysis 37 (2014), 475–482.
27. Hughes-Austin, J.M., Wassel, C.L., Jimenez, J., et al. The relationship between adiposity-associated inflammation and coronary artery and abdominal aortic calcium differs by strata of central adiposity: the Multi-Ethnic Study of Atherosclerosis (MESA). Vasc. Med. 19 (2014), 264–271.
28. Lindmark, E., Diderholm, E., Wallentin, L., et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 286 (2001), 2107–2113.
29. Ridker, P.M., Rifai, N., Stampfer, M.J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000), 1767–1772.
30. Zacho, J., Tybjaerg-Hansen, A., Jensen, J.S., et al. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359 (2008), 1897–1908.
31. Elliott, P., Chambers, J.C., Zhang, W., et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302 (2009), 37–48.
32. Wieckowska, A., Papouchado, B.G., Li, Z., et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 103 (2008), 1372–1379.
33. Rolla, S., Alchera, E., Imarisio, C., et al. The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice. Clin. Sci. (Lond.) 130 (2016), 193–203.
34. Paredes-Turrubiarte, G., Gonzalez-Chavez, A., Perez-Tamayo, R., et al. Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients. Clin. Exp. Med. 16 (2016), 193–202.
35. Hamirani, Y.S., Pandey, S., Rivera, J.J., et al. Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 201 (2008), 1–7.
36. Saremi, A., Anderson, R.J., Luo, P., et al. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis 203 (2009), 610–614.
37. Zimmermann, E., Anty, R., Tordjman, J., et al. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J. Hepatol. 55 (2011), 660–665.
38. Resch, U., Winsauer, G., Hofer-Warbinek, R., et al. X-linked inhibitor of apoptosis protein regulates human interleukin-6 in umbilical vein endothelial cells via stimulation of the nuclear factor-kappaB and MAP kinase signaling pathways. Pharmacol. Rep. 58:Suppl (2006), 111–117.
39. Kaneko, K., Kanda, T., Yokoyama, T., et al. Expression of interleukin-6 in the ventricles and coronary arteries of patients with myocardial infarction. Res. Commun. Mol. Pathol. Pharmacol. 97 (1997), 3–12.
40. Asrih, M., Jornayvaz, F.R., Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J. Endocrinol. 218 (2013), R25–36.
41. Ross, R., Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 340 (1999), 115–126.
42. Zhong, L., Chen, J.J., Chen, J., et al. Nonalcoholic fatty liver disease: quantitative assessment of liver fat content by computed tomography, magnetic resonance imaging and proton magnetic resonance spectroscopy. J. Dig. Dis. 10 (2009), 315–320.
43. Nash, S.D., Cruickshanks, K.J., Zhan, W., et al. Long-term assessment of systemic inflammation and the cumulative incidence of age-related hearing impairment in the epidemiology of hearing loss study. J. Gerontol. A Biol. Sci. Med. Sci. 69 (2014), 207–214.
44. Ridker, P.M., Everett, B.M., Thuren, T., et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N. Engl. J. Med. 377 (2017), 1119–1131.